Polen Capital Management
ADPT icon

Polen Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

Polen Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.2M Sell
102,457
-13,594
-12% -$208K 0.02% 119
2026
Q1 		$1.61M Sell
116,051
-209,716
-64% -$3.34M 0.01% 116
2025
Q4 		$5.29M Buy
325,767
+34,570
+12% +$564K 0.02% 57
2025
Q3 		$4.36M Buy
291,197
+148,940
+105% +$1.81M 0.01% 67
2025
Q2 		$1.66M Buy
+142,257
New +$1.29M 0.01% 94

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Polen Capital Management's ADPT Position: Q2 2026 in Review

Polen Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 12% in Q2 2026, selling an estimated $208K and leaving 102,457 shares worth $2.2M. The position accounts for 0.02% of the portfolio, ranked #119.

Polen Capital Management first reported a position in ADPT in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.29M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • Polen Capital Management held 102,457 shares of Adaptive Biotechnologies worth $2.2M as of Q2 2026.
  • Polen Capital Management sold 13,594 Adaptive Biotechnologies shares in Q2 2026, an estimated $208K.
  • Adaptive Biotechnologies made up 0.02% of Polen Capital Management's portfolio in Q2 2026, its #119 holding.
  • Polen Capital Management first reported a position in Adaptive Biotechnologies in Q2 2025 and has held it in 5 quarters since.
  • Polen Capital Management's Adaptive Biotechnologies position peaked at $5.29M in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Polen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.